SEC filingsOct 12, 2026 to Oct 19, 2026: insiders reported 840 purchases and sales across 212 companies.840 insider purchases and sales in 7 daysSee the filings →
HornScout

Company profile

FENC

Fennec Pharmaceuticals Inc.
NASDAQHealth Care

Latest close: 9.98 USD · Oct 16, 2026 · 1 year · split-adjusted

On the price, the facts of the public record■Insider buy□Insider sell
With an account, also○dividends▲splits◌next earningswith an account

End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.

Latest on record

The most recent facts, as filed.

Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.

  1. Sep 17, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
  2. Sep 15, 2026Reported sale · Form 4Marco Maria Brughera · $160.0KOpen the filing ↗
  3. Sep 15, 2026Notice of sale · Form 144MARCO BRUGHERA · Director · $160.1KOpen the filing ↗

In numbers

What this profile holds, counted.

Closes · 1 year250
SEC filings on record80013 flagged findings
Reported transactions (Form 4)80since Mar 28, 2025 · and 1 other holding
Corporate events (8-K)30since May 4, 2020

What the record says

Description, identity and filings, each with its source.

Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.

SEC record

SEC dossier

What this company has filed with the SEC, in plain language.

The 25 most recent filings (of 800)

Everything filed

Every SEC filing, newest first, with what it is. Below, each type with its own explanation.

800 filings on record, the oldest from Nov 10, 04.

Listing the 25 most recent filings of the 800 on record.

8-Ks, explained

Stress3Structure42Governance23
  • May 18, 26GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
  • Apr 28, 26GovernanceA senior executive left or was appointed8-K 5.02 ↗
  • Structure4 material agreements entered2024 – 2025show all 4hide
    • Nov 19, 25StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
    • Nov 18, 25StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
    • Nov 17, 25StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
    • Dec 20, 24StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Governance3 senior executive changes2024show all 3hide
    • Oct 30, 24GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
    • Aug 7, 24GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
    • Jul 2, 24GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • Mar 21, 24StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Dec 6, 23StructureEntered a material agreement+4 more in the same filing8-K 1.01 ↗
  • Aug 7, 23GovernanceA senior executive left or was appointed+1 more in the same filing8-K/A 5.02 ↗
  • Aug 4, 23GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
  • Structure4 material agreements entered2022show all 4hide
    • Sep 26, 22StructureEntered a material agreement+4 more in the same filing8-K 1.01 ↗
    • Aug 22, 22StructureEntered a material agreement+4 more in the same filing8-K 1.01 ↗
    • Aug 1, 22StructureEntered a material agreement+4 more in the same filing8-K 1.01 ↗
    • Jan 31, 22StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
  • Jan 31, 22GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
  • Structure4 material agreements entered2020 – 2021show all 4hide
    • Jun 24, 21StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
    • Oct 30, 20StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
    • Jun 26, 20StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
    • May 4, 20StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗

The record reaches back to Feb 22, 07.

Notable in the record

Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.

  • Nov 2, 10StressPast accounts declared unreliable and being restated+1 more in the same filing8-K 4.02 ↗
  • Jan 13, 09StressListing notice (8-K 3.01)+1 more in the same filing8-K 3.01 ↗
  • Dec 11, 08StressListing notice (8-K 3.01)+2 more in the same filing8-K 3.01 ↗

The full record holds 3 stress filings.

Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.

Ownership and control

Schedule 13G: short-form filing

The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.

  • Rosalind Advisors, Inc.9.6%Jun 30, 26SCHEDULE 13G/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum. · 3 earlier filings
  • Kam Lawrence8.2%Dec 31, 25SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum.
  • Southpoint Master Fund, LP8.0%Dec 31, 25SCHEDULE 13G/A ↗6 co-filers on this document — the figure is the largest single stake, not their sum.
  • Orin Hirschman5.7%Mar 31, 26SCHEDULE 13G ↗2 co-filers on this document — the figure is the largest single stake, not their sum.
  • Solas Capital Management, LLC5.4%Jun 30, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 3 earlier filings
show one more holderhide
  • DG Capital Management, LLC4.1%Dec 31, 24SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum.

Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.

Sale intention announced

On Sep 15, MARCO BRUGHERA filed notice of intent to sell up to $160K. That is about 0.04% of shares outstanding. It is filed under a scheduled plan (10b5-1), arranged in advance.

A notice is not a sale: it may not go ahead, may happen in part, or at a different price.

After the notice, they sold $160K on Sep 15, per their Form 4. That is 100% of the shares announced so far, and the window is still open.

View notice (Form 144) ↗+5 more recent notices · 5 with a later sale

SEC record

Insider transactions

Buys and sells reported by officers, directors and major shareholders on SEC Form 4.

Buys and sells

  • Sep 15, 26Sell$160KMarco Maria Brughera↗
  • Sep 1, 26Sell$121KRosty Raykov↗
  • Aug 31, 26Sell$146KPierre Sargis SayadChief Medical Officer↗
  • Aug 27, 26Sell$884KRobert AndradeCHIEF FINANCIAL OFFICER↗
  • Aug 3, 26Sell$96KRosty Raykov↗
  • Jul 1, 26Sell$100KRosty Raykov↗
  • Jun 1, 26Sell$94KRosty Raykov↗
Stock compensation, tax and giftsshow the 33 other transactionshide

Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.

  • Oct 12, 26Compensation$21KRobert AndradeCHIEF FINANCIAL OFFICER↗
  • Oct 12, 26Compensation$12KJeffrey S. HackmanChief Executive Officer↗
  • Oct 12, 26Compensation$13KTerry L EvansChief Commercial Officer↗
  • Oct 12, 26Compensation$21KPierre Sargis SayadChief Medical Officer↗
  • Oct 12, 26Compensation$22KChristiana Marie CioffiChief Strategy Officer↗
  • Sep 30, 26Compensationamount n/aRobert AndradeCHIEF FINANCIAL OFFICER↗
  • Sep 30, 26Compensationamount n/aJeffrey S. HackmanChief Executive Officer↗
  • Sep 30, 26Compensationamount n/aTerry L EvansChief Commercial Officer↗
  • Sep 30, 26Compensationamount n/aPierre Sargis SayadChief Medical Officer↗
  • Sep 30, 26Compensationamount n/aChristiana Marie CioffiChief Strategy Officer↗
  • Sep 15, 26Compensation$33KMarco Maria Brughera↗
  • Aug 31, 26Compensationamount n/aRobert AndradeCHIEF FINANCIAL OFFICER↗
  • Aug 31, 26Compensationamount n/aJeffrey S. HackmanChief Executive Officer↗
  • Aug 31, 26Compensationamount n/aTerry L EvansChief Commercial Officer↗
  • Aug 31, 26Compensationamount n/aPierre Sargis SayadChief Medical Officer↗
  • Aug 31, 26Compensationamount n/aChristiana Marie CioffiChief Strategy Officer↗
  • Aug 31, 26Compensationamount n/aRosty Raykov↗
  • Aug 28, 26Compensation$112KRobert AndradeCHIEF FINANCIAL OFFICER↗
  • Jul 31, 26Compensationamount n/aRobert AndradeCHIEF FINANCIAL OFFICER↗
  • Jul 31, 26Compensationamount n/aRosty Raykov↗
  • Jul 31, 26Compensationamount n/aJeffrey S. HackmanChief Executive Officer↗
  • Jul 31, 26Compensationamount n/aTerry L EvansChief Commercial Officer↗
  • Jul 31, 26Compensationamount n/aPierre Sargis SayadChief Medical Officer↗
  • Jul 31, 26Compensationamount n/aChristiana Marie CioffiChief Strategy Officer↗
  • Jul 1, 26Compensationamount n/aRosty Raykov↗
  • Jul 1, 26Compensation$38KRosty Raykov↗
  • Jun 30, 26Compensationamount n/aRobert AndradeCHIEF FINANCIAL OFFICER↗
  • Jun 30, 26Compensationamount n/aJeffrey S. HackmanChief Executive Officer↗
  • Jun 30, 26Compensationamount n/aTerry L EvansChief Commercial Officer↗
  • Jun 30, 26Compensationamount n/aPierre Sargis SayadChief Medical Officer↗
  • Jun 30, 26Compensationamount n/aChristiana Marie CioffiChief Strategy Officer↗
  • Jun 1, 26Compensation$38KRosty Raykov↗
  • May 31, 26Compensationamount n/aRobert AndradeCHIEF FINANCIAL OFFICER↗

The full record holds 251 transactions and goes back to Mar 3, 23.

Its sector and its market

Fennec Pharmaceuticals Inc. among Health Care companies

The profile shows what is on record. Context and Radar place the company among those of its sector and region.

With an account you also get

  • The four engines — growth, trend, risk and context — each with its word and its score.
  • The risk band and the sector phase.
  • The company's fundamentals and accounts.
  • Watchlist: your list of companies, with the «since you follow it» figure.

The research continues

The profile tells the story. The market sets the scene.

From Fennec Pharmaceuticals Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.

  1. Place it in its market

    Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.

    See how Context works →
  2. See what deserves a closer look

    Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.

    See how Radar works →
  3. Keep the why

    Follow Fennec Pharmaceuticals Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.

    See an example review →

Coverage

What sits behind this page.

Where each figure comes from and how far it reaches.

Prices
End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
Series quality
250 clean closes in the period.
SEC records
800 documents on file, from Nov 10, 2004 to Oct 13, 2026.
Company description
No description available.
This page
Generated on Oct 19, 2026; refreshed through the day.

Start at your own pace

Explore first. Go deeper with access.

Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.

Compare plans →
  • No account

    This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.

  • Pro

    What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.

  • Pro+

    Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.

Are the prices real time?

No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.

Which SEC documents appear here?

Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.

Why does a European company show no SEC records?

It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.

Before forming a view on a company,
read what is on record.

One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.

Access by invitation while the beta lasts. Not advice: the profile shows what is on record; it does not recommend.

Fennec Pharmaceuticals Inc. (FENC): stock price history, insider trades and SEC filings — HornScout